Ensign Peak Advisors
CORT icon

Ensign Peak Advisors’s Corcept Therapeutics CORT Stock Holding History

Ensign Peak Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$442K Sell
5,089
-66,692
-93% -$4.03M ﹤0.01% 1029
2026
Q1 		$2.89M Buy
71,781
+15,231
+27% +$570K 0.01% 640
2025
Q4 		$1.97M Sell
56,550
-16,864
-23% -$1.32M ﹤0.01% 703
2025
Q3 		$6.1M Sell
73,414
-13,805
-16% -$999K 0.01% 557
2025
Q2 		$6.4M Buy
87,219
+19,786
+29% +$1.43M 0.01% 585
2025
Q1 		$7.7M Buy
67,433
+19,504
+41% +$1.19M 0.01% 531
2024
Q4 		$2.42M Buy
47,929
+11,040
+30% +$578K ﹤0.01% 862
2024
Q3 		$1.71M Hold
36,889
– – ﹤0.01% 1019
2024
Q2 		$1.2M Hold
36,889
– – ﹤0.01% 1168
2024
Q1 		$929K Sell
36,889
-1,861
-5% -$44K ﹤0.01% 1377
2023
Q4 		$1.26M Hold
38,750
– – ﹤0.01% 1204
2023
Q3 		$1.06M Hold
38,750
– – ﹤0.01% 1160
2023
Q2 		$862K Hold
38,750
– – ﹤0.01% 1380
2023
Q1 		$839K Buy
38,750
+1,250
+3% +$27.4K ﹤0.01% 1390
2022
Q4 		$762K Buy
37,500
+9,500
+34% +$238K ﹤0.01% 1389
2022
Q3 		$718K Sell
28,000
-10,750
-28% -$288K ﹤0.01% 1261
2022
Q2 		$921K Hold
38,750
– – ﹤0.01% 1150
2022
Q1 		$873K Hold
38,750
– – ﹤0.01% 1282
2021
Q4 		$767K Sell
38,750
-48,650
-56% -$987K ﹤0.01% 1412
2021
Q3 		$1.72M Hold
87,400
– – ﹤0.01% 1207
2021
Q2 		$1.92M Buy
87,400
+1,800
+2% +$40.1K ﹤0.01% 1153
2021
Q1 		$2.04M Buy
85,600
+33,300
+64% +$889K ﹤0.01% 1105
2020
Q4 		$1.37M Buy
52,300
+17,800
+52% +$375K ﹤0.01% 1261
2020
Q3 		$600K Hold
34,500
– – ﹤0.01% 1482
2020
Q2 		$580K Hold
34,500
– – ﹤0.01% 1431
2020
Q1 		$410K Buy
+34,500
New +$427K ﹤0.01% 1433

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ensign Peak Advisors's CORT Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Corcept Therapeutics (CORT) stake by 93% in Q2 2026, selling an estimated $4.03M and leaving 5,089 shares worth $442K. The position accounts for ﹤0.01% of the portfolio, ranked #1029.

Ensign Peak Advisors first reported a position in CORT in Q1 2020 and has held it in 26 quarters since. The position peaked at $7.7M in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Ensign Peak Advisors held 5,089 shares of Corcept Therapeutics worth $442K as of Q2 2026.
  • Ensign Peak Advisors sold 66,692 Corcept Therapeutics shares in Q2 2026, an estimated $4.03M.
  • Corcept Therapeutics made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1029 holding.
  • Ensign Peak Advisors first reported a position in Corcept Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Ensign Peak Advisors's Corcept Therapeutics position peaked at $7.7M in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.